Overexpression or enhanced catalytic activity of DNMT1, DNMT3a, and DNMT3b has been observed in multiple cancers, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), glioma, and breast, gastric, colorectal, hepatocellular, pancreatic, prostate, and lung cancers [20]. This evidence concerns the gene DNMT3B and chronic myelogenous leukemia, BCR-ABL1 positive.